Biospecimen Reporting for Improved Study Quality (BRISQ)

被引：109

作者：

Moore, Helen M. ^{[2
]}

Kelly, Andrea B. ^{[3
]}

Jewell, Scott D. ^{[4
]}

McShane, Lisa M. ^{[5
]}

Clark, Douglas P. ^{[1
]}

Greenspan, Renata ^{[6
]}

Hayes, Daniel F. ^{[7
]}

Hainaut, Pierre ^{[8
]}

Kim, Paula ^{[9
]}

Mansfield, Elizabeth A. ^{[10
]}

Potapova, Olga ^{[11
]}

Riegman, Peter ^{[12
]}

Rubinstein, Yaffa ^{[13
]}

Seijo, Edward ^{[14
]}

Somiari, Stella ^{[15
]}

Watson, Peter ^{[16
]}

Weier, Heinz-Ulrich ^{[17
]}

Zhu, Claire ^{[18
]}

Vaught, Jim ^{[2
]}

机构：

[1] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA

[2] Natl Canc Inst, Off Biorepositories & Biospecimen Res, Bethesda, MD USA

[3] Rose Li & Associates Inc, Bethesda, MD USA

[4] Van Andel Res Inst, Program Biospecimen Sci, Grand Rapids, MI USA

[5] NCI, Div Canc Treatment & Diag, Biometr Res Branch, Bethesda, MD 20892 USA

[6] Henry M Jackson Fdn Adv Mil Med, US Mil Canc Inst, Rockville, MD USA

[7] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[8] World Hlth Org, IARC, Lyon, France

[9] Paula Kim Inc, TRAC, Solana Beach, CA USA

[10] US Dept HHS, Ctr Devices & Radiol Hlth, US FDA, Silver Spring, MD USA

[11] Cureline Inc, San Francisco, CA USA

[12] Erasmus MC Tissue Bank, Dept Pathol, Rotterdam, Netherlands

[13] NIH, Off Rare Dis Res, Bethesda, MD 20892 USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[15] Windber Res Inst, Windber, PA USA

[16] British Columbia Canc Agcy, Vancouver Isl Ctr, Victoria, BC, Canada

[17] US DOE, Div Life Sci, Lawrence Berkeley Natl Lab, Berkeley, CA USA

[18] NCI, Canc Prevent Div, Bethesda, MD 20892 USA

来源：

CANCER CYTOPATHOLOGY | 2011年 / 119卷 / 02期

基金：

美国国家卫生研究院;

关键词：

BRISQ; best practices; biobank; biospecimen; human; quality; research; guidelines; APPROACHING CLINICAL PROTEOMICS; FUTURE FIELDS; CURRENT STATE; TISSUE;

D O I：

10.1002/cncy.20147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Human biospecimens are subjected to collection, processing, and storage that can significantly alter their molecular composition and consistency. These biospecimen preanalytical factors, in turn, influence experimental outcomes and the ability to reproduce scientific results. Currently, the extent and type of information specific to the biospecimen preanalytical conditions reported in scientific publications and regulatory submissions varies widely. To improve the quality of research that uses human tissues, it is crucial that information on the handling of biospecimens be reported in a thorough, accurate, and standardized manner. The Biospecimen Reporting for Improved Study Quality (BRISQ) recommendations outlined herein are intended to apply to any study in which human biospecimens are used. The purpose of reporting these details is to supply others, from researchers to regulators, with more consistent and standardized information to better evaluate, interpret, compare, and reproduce the experimental results. The BRISQ guidelines are proposed as an important and timely resource tool to strengthen communication and publications on biospecimen-related research and to help reassure patient contributors and the advocacy community that their contributions are valued and respected. Cancer (Cancer Cytopathol) 2011;119:92-101. Published 2011 by the American Cancer Society.*

引用

页码：92 / 101

页数：10

共 11 条

[1] Approaching Clinical Proteomics: Current State and Future Fields of Application in Cellular Proteomics [J].

Apweiler, Rolf ;

Aslanidis, Charalampos ;

Deufel, Thomas ;

Gerstner, Andreas ;

Hansen, Jens ;

Hochstrasser, Dennis ;

Kellner, Roland ;

Kubicek, Markus ;

Lottspeich, Friedrich ;

Maser, Edmund ;

Mewes, Hans-Werner ;

Meyer, Helmut E. ;

Muellner, Stefan ;

Mutter, Wolfgang ;

Neumaier, Michael ;

Nollau, Peter ;

Nothwang, Hans G. ;

Ponten, Fredrik ;

Radbruch, Andreas ;

Reinert, Knut ;

Rothe, Gregor ;

Stockinger, Hannes ;

Tarnok, Attila ;

Taussig, Mike J. ;

Thiel, Andreas ;

Thiery, Joachim ;

Ueffing, Marius ;

Valet, Guenther ;

Vandekerckhove, Joel ;

Wagener, Christoph ;

Wagner, Oswald ;

Schmitz, Gerd .

CYTOMETRY PART A, 2009, 75A (10) :816-832

[2] Approaching clinical proteomics: current state and future fields of application in fluid proteomics [J].

Apweiler, Rolf ;

Aslanidis, Charalampos ;

Deufel, Thomas ;

Gerstner, Andreas ;

Hansen, Jens ;

Hochstrasser, Dennis ;

Kellner, Roland ;

Kubicek, Markus ;

Lottspeich, Friedrich ;

Maser, Edmund ;

Mewes, Hans-Werner ;

Meyer, Helmut E. ;

Muellner, Stefan ;

Mutter, Wolfgang ;

Neumaier, Michael ;

Nollau, Peter ;

Nothwang, Hans G. ;

Ponten, Fredrik ;

Radbruch, Andreas ;

Reinert, Knut ;

Rothe, Gregor ;

Stockinger, Hannes ;

Tarnok, Attila ;

Taussig, Mike J. ;

Thiel, Andreas ;

Thiery, Joachim ;

Ueffing, Marius ;

Valet, Guenther ;

Vandekerckhove, Joel ;

Verhuven, Wiltrud ;

Wagener, Christoph ;

Wagner, Oswald ;

Schmitz, Gerd .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2009, 47 (06) :724-744

[3] HER-2/neu detection in fine-needle aspirates of breast cancer - Fluorescence in situ hybridization and immunocytochemical analysis [J].

Beatty, BG ;

Bryant, R ;

Wang, WC ;

Ashikaga, T ;

Gibson, PC ;

Leiman, G ;

Weaver, DL .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 122 (02) :246-255

[4] Standard Preanalytical Coding for Biospecimens: Defining the Sample PREanalytical Code [J].

Betsou, Fotini ;

Lehmann, Sylvain ;

Ashton, Garry ;

Barnes, Michael ;

Benson, Erica E. ;

Coppola, Domenico ;

DeSouza, Yvonne ;

Eliason, James ;

Glazer, Barbara ;

Guadagni, Fiorella ;

Harding, Keith ;

Horsfall, David J. ;

Kleeberger, Cynthia ;

Nanni, Umberto ;

Prasad, Anil ;

Shea, Kathi ;

Skubitz, Amy ;

Somiari, Stella ;

Gunter, Elaine .

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (04) :1004-1011

[5] Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability [J].

Espina, Virginia ;

Mueller, Claudius ;

Edmiston, Kirsten ;

Sciro, Manuela ;

Petricoin, Emanuel F. ;

Liotta, Lance A. .

PROTEOMICS CLINICAL APPLICATIONS, 2009, 3 (08) :874-882

[6] Reporting recommendations for tumor marker prognostic studies (REMARK) [J].

McShane, LM ;

Altman, DG ;

Sauerbrei, W ;

Taube, SE ;

Gion, M ;

Clark, GM .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (16) :1180-1184

[7]

Moore Helen M, 2009, Cancer Res, V69, P6770, DOI 10.1158/0008-5472.CAN-09-1795

[8] Sources of Bias in Specimens for Research About Molecular Markers for Cancer [J].

Ransohoff, David F. ;

Gourlay, Margaret L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (04) :698-704

[9] Informed consent in biobank research: A deliberative approach to the debate [J].

Secko, David M. ;

Preto, Nina ;

Niemeyer, Simon ;

Burgess, Michael M. .

SOCIAL SCIENCE & MEDICINE, 2009, 68 (04) :781-789

[10] Effect of fixatives and tissue processing on the content and integrity of nucleic acids [J].

Srinivasan, M ;

Sedmak, D ;

Jewell, S .

AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (06) :1961-1971

← 1 2 →